93 related articles for article (PubMed ID: 36453626)
21. Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States.
Bruno DS; Hess LM; Li X; Su EW; Patel M
JCO Precis Oncol; 2022 Jun; 6():e2100427. PubMed ID: 35737912
[TBL] [Abstract][Full Text] [Related]
22. National cost of trauma care by payer status.
Velopulos CG; Enwerem NY; Obirieze A; Hui X; Hashmi ZG; Scott VK; Cornwell EE; Schneider EB; Haider AH
J Surg Res; 2013 Sep; 184(1):444-9. PubMed ID: 23800441
[TBL] [Abstract][Full Text] [Related]
23. Biomarker Testing, Targeted Therapy and Clinical Trial Participation by Race Among Patients With Lung Cancer: A Real-World Medicaid Database Study.
Bruno DS; Li X; Hess LM
JTO Clin Res Rep; 2024 Mar; 5(3):100643. PubMed ID: 38496377
[TBL] [Abstract][Full Text] [Related]
24. Cost of Bleeding-related Episodes in Adult Patients With Primary Immune Thrombocytopenia: A Population-based Retrospective Cohort Study of Administrative Claims Data for Commercial Payers in the United States.
Lin J; Zhang X; Li X; Chandler D; Altomare I; Wasser JS; Cetin K
Clin Ther; 2017 Mar; 39(3):603-609.e1. PubMed ID: 28190600
[TBL] [Abstract][Full Text] [Related]
25. Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers.
Chawla A; Peeples M; Li N; Anhorn R; Ryan J; Signorovitch J
J Med Econ; 2018 Jun; 21(6):543-552. PubMed ID: 29295635
[TBL] [Abstract][Full Text] [Related]
26. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ
J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144
[TBL] [Abstract][Full Text] [Related]
27. Out-of-Pocket Costs Among Patients With a New Cancer Diagnosis Enrolled in High-Deductible Health Plans vs Traditional Insurance.
Fu SJ; Rose L; Dawes AJ; Knowlton LM; Ruddy KJ; Morris AM
JAMA Netw Open; 2021 Dec; 4(12):e2134282. PubMed ID: 34935922
[TBL] [Abstract][Full Text] [Related]
28. Patient out-of-pocket payments for oral oncolytics: results from a 2009 US claims data analysis.
Raborn ML; Pelletier EM; Smith DB; Reyes CM
Am J Manag Care; 2012 May; 18(5 Spec No. 2):SP57-64. PubMed ID: 22693982
[TBL] [Abstract][Full Text] [Related]
29. Total and out-of-pocket costs of different primary management strategies in ovarian cancer.
Suidan RS; He W; Sun CC; Zhao H; Rauh-Hain JA; Fleming ND; Lu KH; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2019 Aug; 221(2):136.e1-136.e9. PubMed ID: 30965052
[TBL] [Abstract][Full Text] [Related]
30. Healthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United States.
Fu AZ; Jhaveri M
J Med Econ; 2012; 15(4):688-94. PubMed ID: 22397589
[TBL] [Abstract][Full Text] [Related]
31. Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC.
Gross CP; Meyer CS; Ogale S; Kent M; Wong WB
J Natl Compr Canc Netw; 2022 May; 20(5):479-487.e2. PubMed ID: 35545174
[TBL] [Abstract][Full Text] [Related]
32. Real-World Cost of Care for Commercially Insured versus Medicare Patients with Metastatic Pancreatic Cancer Who Received Guideline-Recommended Therapies.
Tomicki S; Dieguez G; Latimer H; Cockrum P; Kim G
Am Health Drug Benefits; 2021 Jun; 14(2):70-78. PubMed ID: 34267862
[TBL] [Abstract][Full Text] [Related]
33. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
34. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy.
Vera-Llonch M; Weycker D; Glass A; Gao S; Borker R; Barber B; Oster G
BMC Health Serv Res; 2011 Nov; 11():305. PubMed ID: 22074001
[TBL] [Abstract][Full Text] [Related]
35. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.
Karve SJ; Price GL; Davis KL; Pohl GM; Smyth EN; Bowman L
BMC Health Serv Res; 2014 Nov; 14():555. PubMed ID: 25392276
[TBL] [Abstract][Full Text] [Related]
36. The prevalence of lower limb loss in children and associated costs of prosthetic devices: A national study of commercial insurance claims.
McLarney M; Pezzin LE; McGinley EL; Prosser L; Dillingham TR
Prosthet Orthot Int; 2021 Apr; 45(2):115-122. PubMed ID: 33158398
[TBL] [Abstract][Full Text] [Related]
37. Assessment of the Risk and Economic Burden of Surgical Site Infection Following Colorectal Surgery Using a US Longitudinal Database: Is There a Role for Innovative Antimicrobial Wound Closure Technology to Reduce the Risk of Infection?
Leaper DJ; Holy CE; Spencer M; Chitnis A; Hogan A; Wright GWJ; Po-Han Chen B; Edmiston CE
Dis Colon Rectum; 2020 Dec; 63(12):1628-1638. PubMed ID: 33109910
[TBL] [Abstract][Full Text] [Related]
38. The Role of Commercial Health Insurance Characteristics in Bariatric Surgery Utilization.
Chhabra KR; Fan Z; Chao GF; Dimick JB; Telem DA
Ann Surg; 2021 Jun; 273(6):1150-1156. PubMed ID: 31714318
[TBL] [Abstract][Full Text] [Related]
39. Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis.
Bonafede M; Anaissie E; Evans K; Itzler R
BMC Health Serv Res; 2021 Oct; 21(1):1125. PubMed ID: 34666775
[TBL] [Abstract][Full Text] [Related]
40. Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Arnold RJG
Value Health; 2018 Nov; 21(11):1278-1285. PubMed ID: 30442274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
